Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab

被引：64
|
作者：
Cousin, S. [1 ,2 ]
Toulmonde, M. [1 ,2 ]
Kind, M. [3 ]
Cazeau, A. -L. [4 ]
Bechade, D. [2 ]
Coindre, J. -M. [5 ]
Italiano, A. [1 ,2 ]
机构：
[1] Inst Bergonie, Early Phase Trials Unit, Bordeaux, France
[2] Inst Bergonie, Dept Med, Bordeaux, France
[3] Inst Bergonie, Dept Radiol, Bordeaux, France
[4] Inst Bergonie, Dept Nucl Med, Bordeaux, France
[5] Inst Bergonie, Dept Pathol, Bordeaux, France
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷 / 06期
关键词：
METASTATIC MELANOMA; IPILIMUMAB; PATIENT;
D O I：
10.1093/annonc/mdw125
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1178 / 1179
页数：2
相关论文
共 50 条
  • [31] Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma
    Hersey, Peter
    Gowrishankar, Kavitha
    FUTURE ONCOLOGY, 2015, 11 (01) : 133 - 140
  • [32] Ipilimumab in anti-PD1 refractory metastatic melanoma: a report of eight cases
    Jacobsoone-Ulrich, Aurelie
    Jamme, Philippe
    Alkeraye, Salim
    Dzwiniel, Veronique
    Faure, Emmanuel
    Templier, Carole
    Mortier, Laurent
    MELANOMA RESEARCH, 2016, 26 (02) : 153 - 156
  • [33] Original Research Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy
    Dearden, Helen
    Au, Lewis
    Wang, Daniel Y.
    Zimmer, Lisa
    Eroglu, Zeynep
    Smith, Jessica L.
    Cuvietto, Marcello
    Khoo, Chloe
    Atkinson, Victoria
    Lo, Serigne
    V. Long, Georgina
    Sandhu, Shahneen
    Ascierto, Paolo A.
    Carlino, Matteo S.
    Johnson, Douglas B.
    Larkin, James
    Menzies, Alexander M.
    EUROPEAN JOURNAL OF CANCER, 2021, 153 : 168 - 178
  • [34] Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma
    Feng, Duan
    Hui, Xie
    Shi-Chun, Lu
    Yan-Hua, Bai
    Li, Cui
    Xiao-Hui, Li
    Jie-Yu, Yan
    ONCOTARGET, 2017, 8 (57) : 96649 - 96655
  • [35] Robust immunoscore model to predict the response to anti-PD1 therapy in melanoma
    Nie, Run-Cong
    Yuan, Shu-Qiang
    Wang, Yun
    Chen, Ying-Bo
    Cai, Yan-Yu
    Chen, Shi
    Li, Shu-Man
    Zhou, Jie
    Chen, Guo-Ming
    Luo, Tian-Qi
    Zhou, Zhi-Wei
    Li, Yuan-Fang
    AGING-US, 2019, 11 (23): : 11576 - 11590
  • [36] Acquired amegakaryocytic thrombocytopenic purpura possibly induced by anti-PD-1 antibody
    Iyama, Satoshi
    Takada, K.
    Yoshida, M.
    Takahashi, D.
    Kobune, M.
    ANNALS OF HEMATOLOGY, 2020, 99 (07) : 1669 - 1670
  • [37] The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies
    Ciccarese, Chiara
    Iacovelli, Roberto
    Bria, Emilio
    Modena, Alessandra
    Massari, Francesco
    Brunelli, Matteo
    Fantinel, Emanuela
    Bimbatti, Davide
    Zamboni, Giulia A.
    Artibani, Walter
    Tortora, Giampaolo
    IMMUNOTHERAPY, 2017, 9 (07) : 579 - 587
  • [38] Complete response of metastatic melanoma in a patient with Crohn's disease simultaneously receiving anti-47 and anti-PD1 antibodies
    Frohne, Christopher C.
    Llano, Ernesto M.
    Perkovic, Ashley
    Cohen, Russell D.
    Luke, Jason J.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [39] Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma
    Machiraju, Devayani
    Schaefer, Sarah
    Hassel, Jessica C.
    LIFE-BASEL, 2021, 11 (12):
  • [40] Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma
    Lee, J. H.
    Long, G. V.
    Boyd, S.
    Lo, S.
    Menzies, A. M.
    Tembe, V.
    Guminski, A.
    Jakrot, V.
    Scolyer, R. A.
    Mann, G. J.
    Kefford, R. F.
    Carlino, M. S.
    Rizos, H.
    ANNALS OF ONCOLOGY, 2017, 28 (05) : 1130 - 1136
12345